Alphamab Oncology
Alphamab Oncology (HKSE: 9966) is trading at HK$8.00, about ₹98 at today's HKD/INR rate, as of 28 Sep 2026, 4:08 AM ET, down 4.02% today. Indian residents can buy Alphamab Oncology from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$7.90
Today's high
HK$8.35
52 week low
HK$6.23
52 week high
HK$15.75
9966 opened at HK$8.35, closed previously at HK$8.34, and has traded between HK$6.23 and HK$15.75 over the past 52 weeks.
About
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Key statistics
Avg. volume
1.56M
Market cap
HK$7.75B
P/E Ratio
-39.75
Price-to-sales ratio
12.87
Enterprise value
CN¥6.51B
Free cash flow yield
-2.59%
Debt-to-equity ratio
0.16
Return on equity
-10.27%
ROIC
-10.01%
Beta
0.56
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥551.58M
Earnings per share
-CN¥0.12
Free cash flow
-CN¥153.48M
Net profit margin
-33.79%
Gross margin
76.09%
EBITDA
-CN¥86.31M
Revenue growth
-13.83%
Similar securities
This is not an investment recommendation
How to buy Alphamab Oncology from India
Indian residents can buy Alphamab Oncology shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Alphamab Oncology and place an order
Find Alphamab Oncology by name or by its ticker, 9966, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Alphamab Oncology trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Alphamab Oncology position in HKD and INR. Alphamab Oncology pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Alphamab Oncology from India
Trading and taxes when buying Alphamab Oncology from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneAlphamab Oncology does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Alphamab Oncology stock?
Yes. Alphamab Oncology (9966) has been listed on the Hong Kong Stock Exchange since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Alphamab Oncology share cost in rupees?
One Alphamab Oncology share is HK$8.00 — about ₹98 at an HKD/INR rate of 12.24 on 27 Sep 2026. Both the Alphamab Oncology price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Alphamab Oncology from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Alphamab Oncology?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Alphamab Oncology shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Alphamab Oncology price. Paasa issues a capital-gains statement for your return.
Does Alphamab Oncology pay a dividend?
No. Alphamab Oncology does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Alphamab Oncology from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Alphamab Oncology a Hong Kong SAR China company, and does that change how it is taxed?
Alphamab Oncology trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Alphamab Oncology trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Alphamab Oncology shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Alphamab Oncology holding, its cost and its closing value.
How do I sell Alphamab Oncology and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.